CTNM NASDAQ
Credit Risk of going bust: higher than 50% of companies Debt: 2.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down 99.6%), Contineum Therapeutics, Inc. would be worth roughly what it owes.
Total debt $6.6M against a stock market value of $268.3M.
Distance to default 5.09 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.3M (short-term plus half of long-term), stock volatility 82.1%; Altman Z'' 25.32. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92121
US
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The companyâs lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Stengone Carmine N. | S-Sale | 2,500 | $16.46 | 2026-09-08 |
| Stengone Carmine N. | S-Sale | 2,500 | $16.01 | 2026-08-03 |
| Lorrain Daniel S. | S-Sale | 25 | $16.00 | 2026-07-09 |
| Stengone Carmine N. | S-Sale | 2,500 | $16.00 | 2026-07-08 |
| Lorrain Daniel S. | S-Sale | 5,852 | $15.67 | 2026-07-01 |